7 block­busters: An­a­lysts spot­light 2022’s crop of drugs most like­ly to win top mar­ket­ing sta­tus — 2 drugs dom­i­nate

Every year, the an­a­lysts over at Clar­i­vate is­sue their pre­dic­tions for which drugs will hit block­buster sta­tus.

Now in its 9th year, they’ve got some drugs — ei­ther pend­ing an FDA ap­proval or just won ap­proval, in the case of the asth­ma treat­ment teze­pelum­ab — that they think will be­come block­busters (i.e. hit $1 bil­lion in an­nu­al rev­enue) in the next five years. By the end of 2026, the an­a­lysts are ex­pect­ing about $16 bil­lion in sales from the top 7 drugs, and the top 2 can­di­dates — both from Eli Lil­ly — are pre­dict­ed to have an out-sized bite.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.